News | MRI Breast | February 19, 2016

New MRI Analytics May Offer Quick Breast Cancer Treatment Guidance

Faster, cheaper test predicts who needs chemotherapy or just hormonal regimen

breast MRI, ER-positive breast cancer detection, Case Western Reserve study

Differences in dynamic textural patterns are apparent between a patient with a low recurrence score, left, and a patient with a high recurrence score, right. Image courtesy of Nature Scientific Reports

February 19, 2016 — A new way to analyze magnetic resonance images (MRI) data appears to reliably distinguish between patients who would need only hormonal treatment and those who also need chemotherapy, researchers from Case Western Reserve University report.

The analysis may provide women diagnosed with estrogen positive-receptor (ER-positive) breast cancer —the most common type of breast cancer — answers far faster than current tests and, due to its expected low cost, open the door to this kind of testing worldwide.

The research is published in the journal Nature Scientific Reports.

“In the United States, nearly 70 percent of all breast cancer patients are diagnosed with ER-positive, but the majority don’t need chemotherapy,” said Anant Madabhushi, biomedical engineering professor at Case Western Reserve and research leader.

“Until about 15 years ago, doctors had no way of telling aggressive cancer from non-aggressive, so the majority of women got chemotherapy, which can produce very harsh side effects,” he said.

Since then, a genomic test for differentiating between aggressive and nonaggressive cancer was developed. The test requires doctors to send a biopsy sample to a company that analyzes it and assigns a risk score that the doctors then use to guide treatment.

“The test is used frequently in the United States, but it destroys tissue, requires shipping and costs about $4,000,” said Madabhushi, who is a member of the Case Comprehensive Cancer Center. “The cost puts the test out of reach for people in middle- and low-income countries.”

Madabhushi’s team, which employs big data to study disease, thought they might find useful signals to discern aggressive ER-positive from indolent by mining radiologic data from MRIs.

They analyzed images of 96 ER-positive cancer patients scanned at a hospital in Cleveland or Boston. Each woman had undergone what’s called a dynamic contrast-enhanced MRI, which produces images of tissues as they take up a contrast agent. Each woman had also undergone the genomic test.

Because intensity values regularly used to analyze tissues vary by scanner, the researchers needed a different way to search for signals distinguishing the two categories of patients:

  • They discovered differences in gene expression—molecular changes that appeared as changes in textural patterns in the images; and
  • They converted the dynamic texture changes into quantitative measurements and used differences in the measurements to determine which patients needed chemotherapy and which did not.

In 85 percent of the cases, the conclusions matched those of the genomic test.

“We think the dynamic texture data is robust and reliable,” Madabhushi said. “It allows us to compare apples to apples.”

He expects the test, if further trials validate it, would cost “pennies on the dollar, compared to the $4,000 test.”

For the patient, the test requires an MRI scan, which many doctors already prescribe for those newly diagnosed with cancer. “So the test, for many, doesn’t require the cost of a scan,” Madabhushi said.

He said a computer and program are the tools needed. No tissue would be shipped. Instead of waiting a week or two for results, the wait would be minutes, reducing the stress on patients and allowing them to quickly start treatment, the researchers say.

“With cloud computing and data warehousing, we can analyze images coming in from anywhere in the world, “Madabhushi said. “It breaks down geographic boundaries because everything is electronically transmitted.”

The researchers are seeking funding to evaluate the test further. They want to look at the outcomes for the 96 patients to try to determine how accurately this test and the genomic test predicted who needed chemotherapy and who didn’t. They plan to test scans from more sites to see if the results hold up.

Madabhushi said even if the MRI test proves to make accurate predictions only for patients at extremely low or extremely high need for chemotherapy, the analysis would still serve 30 to 40 percent of patients.

Co-authors on this paper include Tao Wan, Ph.D., professor of school of biological sciences and medical engineering at Beihang University; Boston Medical Center’s B. Nicholas Bloch, M.D., associate professor of radiology, and Carl Jaffe, M.D., professor of radiology; and from Case Western Reserve, Hannah Gilmore, M.D., assistant professor of pathology, Cheryl Thompson, Ph.D., assistant professor of biostatistics and epidemiology, Donna Plecha, M.D., associate professor of radiology, and Lyndsay Harris, M.D., professor of hematology and oncology.

For more information: www.nature.com/srep

Related Content

Older Biologic Age Linked to Elevated Breast Cancer Risk
News | Women's Health | March 19, 2019
Biologic age, a DNA-based estimate of a person’s age, is associated with future development of breast cancer, according...
HeartFlow Analysis Successfully Stratifies Heart Disease Patients at One Year
News | CT Angiography (CTA) | March 19, 2019
Late-breaking results confirm the HeartFlow FFRct (fractional flow reserve computed tomography) Analysis enables...
PET Scans Show Biomarkers Could Spare Some Breast Cancer Patients from Chemotherapy
News | PET Imaging | March 18, 2019
A new study positron emission tomography (PET) scans has identified a biomarker that may accurately predict which...
SyncVision iFR Co-registration from Philips Healthcare maps iFR pressure readings onto angiogram.

SyncVision iFR Co-registration from Philips Healthcare maps iFR pressure readings onto angiogram. Results from an international study presented at #ACC19 show that pressure readings in coronary arteries may identify locations of stenoses remaining after cardiac cath interventions.

Feature | Cardiac Imaging | March 18, 2019 | By Greg Freiherr
As many as one in four patients who undergo cath lab interventions can benefit from a technology that identifies the
Non-Contrast MRI Effective in Monitoring MS Patients
News | Neuro Imaging | March 18, 2019
Brain magnetic resonance imaging (MRI) without contrast agent is just as effective as the contrast-enhanced approach...
Fujifilm Launches Three New Software Tools for Aspire Cristalle Digital Mammography System
Technology | Mammography | March 15, 2019
Fujifilm Medical Systems USA announced it has fulfilled all U.S. Food and Drug Administration (FDA) regulatory...
Bay Labs Announces New Data on EchoGPS, AutoEF AI Software at ACC.19
News | Cardiovascular Ultrasound | March 15, 2019
Artificial intelligence (AI) company Bay Labs announced the presentation of two studies assessing performance of the...
Hologic Receives CE Mark for Three-in-One Omni Hysteroscope
News | Endoscopes | March 14, 2019
Hologic Inc. announced it has received a CE mark in Europe for its Omni hysteroscope, a three-in-one modular scope with...
CT, Mammograms Offer Clues to Preventing Heart Problems After Cancer Treatment
News | Cardio-oncology | March 13, 2019
An imaging procedure commonly performed before starting cancer treatment can provide valuable clues about a patient's...
Sponsored Content | Videos | Artificial Intelligence | March 13, 2019
At RSNA 2018, iCad showed how its...